Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).
1 finding from 1 review
ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Mortality within the trial period · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in mortality within the trial period compared with placebo (low certainty).
1 finding from 1 review
Chronic lung disease · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in chronic lung disease at 28 days compared with placebo (low certainty).
1 finding from 1 review
Hypokalaemia · preterm infants (< 37 weeks GA) at risk of chronic lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease
1 finding from 1 review
Proven sepsis (positive bacterial culture, local or systemic) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
Summary of findings table ‐ Probiotics showed no clear difference in proven sepsis (positive bacterial culture, local or systemic) compared with placebo (low certainty).
1 finding from 1 review
Neonatal mortality · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
Age at full enteral feedings (days) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
Mortality before hospital discharge · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
Non‐pathogenic intestinal microflora (relative abundance) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
All‐cause mortality during hospital stay · neonates with sepsis
Pentoxifylline with antibiotics (any dose or duration) may leads to lower all‐cause mortality during hospital stay compared with placebo or no intervention (low certainty).
1 finding from 1 review
Chronic lung disease · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes chronic lung disease compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes severe intraventricular haemorrhage compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Periventricular leukomalacia · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes periventricular leukomalacia compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Length of hospital stay · neonates with sepsis
Pentoxifylline with antibiotics (any dose or duration) showed no clear difference in length of hospital stay (LOS) in days compared with placebo or no intervention (low certainty).
1 finding from 1 review
Necrotising enterocolitis · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Retinopathy of prematurity · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes retinopathy of prematurity, any stage compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel leads to lower hypoglycaemia (investigator‐defined) compared with placebo (high certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review